Vergoeding 2015-2019 voor ATC-subgroep C09CA : Angiotensine-ii-antagonisten
- Raming voor de totale Zvw-populatie
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| C09CA01 Losartan (Cozaar ®) | 2.629.600 | 2.367.000 | 2.558.600 | 3.053.600 | 5.489.800 |
| C09CA02 Eprosartan (Teveten ®) | 559.570 | 408.410 | 377.310 | 363.030 | 113.280 |
| C09CA03 Valsartan (Diovan ®) | 3.216.600 | 3.109.200 | 3.216.100 | 3.565.300 | 2.695.300 |
| C09CA04 Irbesartan (Aprovel ®) | 3.570.500 | 2.985.900 | 2.522.200 | 2.638.200 | 4.277.500 |
| C09CA06 Candesartan (Atacand ®) | 1.236.600 | 1.109.000 | 1.085.000 | 1.209.700 | 1.775.700 |
| C09CA07 Telmisartan (Micardis ®) | 1.119.300 | 898.830 | 798.200 | 776.290 | 1.285.000 |
| C09CA08 Olmesartan (Olmetec ®) | 2.722.500 | 2.609.700 | 1.839.300 | 691.930 | 581.760 |
| C09CA09 Azilsartanmedoxomil | 920 | . | . | . | . |
| Totaal | 15.055.590 | 13.488.040 | 12.396.710 | 12.298.050 | 16.218.340 |